Q3 Earnings Estimate for OPKO Health Issued By HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK) – Analysts at HC Wainwright raised their Q3 2025 earnings per share estimates for OPKO Health in a research report issued on Monday, April 7th. HC Wainwright analyst Y. Chen now expects that the biotechnology company will earn ($0.07) per share for the quarter, up from their prior forecast of ($0.08). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health’s FY2025 earnings at ($0.29) EPS.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%.

Several other research analysts have also issued reports on OPK. StockNews.com upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd. Barrington Research reiterated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research report on Wednesday, March 12th.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.49 on Thursday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The company’s 50-day simple moving average is $1.69 and its 200-day simple moving average is $1.58. OPKO Health has a one year low of $1.15 and a one year high of $2.04. The stock has a market capitalization of $1.00 billion, a price-to-earnings ratio of -7.84 and a beta of 1.78.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds and other institutional investors have recently made changes to their positions in OPK. Wealth Enhancement Advisory Services LLC raised its stake in shares of OPKO Health by 75.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 12,417 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in OPKO Health by 24.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 753,380 shares of the biotechnology company’s stock worth $1,107,000 after purchasing an additional 148,322 shares during the period. Two Sigma Advisers LP raised its holdings in shares of OPKO Health by 2.3% during the 4th quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after acquiring an additional 8,396 shares in the last quarter. Two Sigma Investments LP raised its holdings in OPKO Health by 136.1% during the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company’s stock valued at $2,422,000 after buying an additional 949,671 shares during the period. Finally, ProShare Advisors LLC increased its stake in OPKO Health by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 91,730 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 30,182 shares during the period. 64.63% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 150,000 shares of the stock in a transaction dated Friday, January 17th. The stock was bought at an average price of $1.47 per share, for a total transaction of $220,500.00. Following the purchase, the chief executive officer now directly owns 213,186,477 shares of the company’s stock, valued at $313,384,121.19. The trade was a 0.07 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders bought a total of 1,339,971 shares of company stock worth $2,098,692 over the last quarter. 49.69% of the stock is currently owned by insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.